Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
Sudarshan Pharma to raise up to ₹72 Cr via Convertible Warrants to Promoters
Sudarshan Pharma Industries' Board has approved raising funds up to ₹72 Crores through the issuance of convertible warrants on a preferential basis to promoters Mr. Hemal Mehta and Mr. Sachin Mehta. Each warrant is convertible into 1 equity share of face value ₹1, priced pursuant to SEBI ICDR Regulations. The fundraise represents approximately 36.9% of the company's net worth (₹195 Cr), which could aid in deleveraging given its ₹392 Cr debt load (D/E of 2.01). The proposal remains subject to shareholder approval at an upcoming Extraordinary General Meeting (EGM).
high confidence
What changedBoard approved issuing up to ₹72 Cr worth of convertible warrants to promoters on a preferential basis.
Why it mattersThe capital infusion signals promoter commitment and provides sizeable equity funding relative to net worth (₹195 Cr), potentially easing balance sheet leverage.
Fundraise Amount: upto Rs.72,00,00,000Face Value per Share: Re.1/-Fundraise vs Net Worth: ~36.9%
📅 Short termMarket may view the promoter capital infusion positively; watch for EGM outcome and exact warrant issue price.
📈 Long termIf successfully converted, the equity cushion will improve the debt-to-equity ratio from 2.01 and support balance sheet health.
⚠ Risk flags
Equity dilution upon conversion of warrants
Shareholder and regulatory approvals still pending
👀 What to Watch
Track the upcoming EGM notice for warrant pricing details and monitor whether proceeds will be deployed toward debt reduction (given current debt of ₹392 Cr).
Sudarshan Pharma Q2 Standalone Net Profit Rises 77% YoY to ₹7.80 Cr; Closes Palghar Unit
Sudarshan Pharma Industries reported standalone revenue from operations of ₹20,551.81 lakhs for Q2 ended September 30, 2026, up 23% YoY from ₹16,708.63 lakhs. Standalone net profit grew 77% YoY to ₹779.51 lakhs compared to ₹440.03 lakhs in Q2 FY25. The company migrated from the BSE SME platform to the Main Boards of BSE and NSE on October 27, 2026. Additionally, the company announced the discontinuation of manufacturing operations at its Palghar unit to rationalize costs.
high confidence
What changedSudarshan Pharma published its Q2 FY27 results, shut down its Palghar manufacturing unit, and successfully migrated to the NSE/BSE Main Boards.
Why it mattersThe Main Board listing broadens institutional visibility, while healthy revenue and profit growth indicate solid demand despite manufacturing footprint restructuring.
Revenue from operations (Q2 Standalone): ₹20,551.81 lakhsNet Profit (Q2 Standalone): ₹779.51 lakhsBasic EPS (Q2): ₹0.32Litigation award received till Sept 30, 2026: ₹7,46,91,069
📅 Short termMarket response may reflect the 77% YoY net profit growth and the recent transition to the NSE and BSE Main Boards.
📈 Long termDiscontinuing the loss-making Palghar facility could structurally improve operating margins, while ongoing FCCB issuances provide expansion capital but introduce dilution risk.
⚠ Risk flags
Discontinuation of Palghar unit reflects prior operational underperformance
Potential equity dilution from remaining FCCB instruments (board approval for up to ₹1,500 crore)
Four foreign subsidiaries were unreviewed by external auditors (certified by management only)
👀 What to Watch
Track the margin improvement and cost rationalization benefits following the closure of the Palghar unit, alongside dilution impacts from potential future FCCB conversions.
📊 Last 7 days — analysed filings by sentiment
positivenegativeneutralwatch
⚠️How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI
⚡ Free FlashFinance Newsletters
AI-powered market intelligence in your inbox — completely free. Pick your topics; max 1 email per topic per day. Unsubscribe anytime.
✅ Everything below is 100% free — no payment, no card, ever.
🎉
You're subscribed!
A welcome email with your topics is on its way. Want it even faster? Join us on Telegram or WhatsApp:
